Drug Manufacturing Bill: 3 Key Notes | Becker’s Hospital Review
- A bipartisan group of senators is again pushing for legislation to address persistent generic drug shortages.
- Gary Peters, D-Mich.; Marsha blackburn, R-Tenn.; Tim Kaine, D-Va.; and Ted Budd, R-N.C., reintroduced the Rolling Active Pharmaceutical Ingredient and Drug Reserve Act.
- A 2023 report indicated that at least 15 medications have been in short supply for over a decade.
Senators are actively working to combat the ongoing generic drug shortages, with a new bipartisan bill designed to bolster domestic drug supply chains. This legislation focuses on two key areas: expanding domestic manufacturing capabilities and building up stockpiles of essential medications. Addressing complex manufacturing issues of low-cost generic drugs is a core priority. News Directory 3 reports the lawmakers’ request to the GAO for investigation into unused domestic manufacturing capacity. Beyond expanding the federal drug stockpile, the investigation also aims to examine innovative production techniques. The bill aims to ensure a more stable supply chain for critical medications. Discover what’s next as this bill moves through the committee and toward a Senate vote – will it resolve these persistent shortages?
Senators Seek to Bolster Generic Drug Supply Chains, Mitigate Shortages
updated June 18, 2025
A bipartisan group of senators is again pushing for legislation to address persistent generic drug shortages. The proposed bill aims to strengthen critical drug supply chains by expanding domestic manufacturing and stockpiles.
Sens. Gary Peters, D-Mich.; Marsha blackburn, R-Tenn.; Tim Kaine, D-Va.; and Ted Budd, R-N.C., reintroduced the Rolling Active Pharmaceutical Ingredient and Drug Reserve Act. The bill would direct the Department of Health and Human Services (HHS) to award contracts to U.S. or allied manufacturers. These contracts would support the maintenance of stockpiles of essential medications and their active ingredients.
A 2023 report indicated that at least 15 medications have been in short supply for over a decade. Many of these are low-cost generic drugs that are complex to manufacture. The senators are focusing on the drug supply chain to resolve these issues.
Beyond expanding the federal drug stockpile, the senators have also requested that the Government Accountability Office (GAO) investigate unused domestic manufacturing capacity. They also want the GAO to examine federal efforts to scale up advanced production techniques.
What’s next
The bill now heads to committee, where it will be debated and perhaps amended before a vote by the full Senate. Its supporters hope the legislation will lead to a more secure and reliable supply of essential generic medications.